UK’s Health and Wealth Strategy Fails as Pharma Looks Elsewhere

The UK government’s long-standing strategy of linking national “health and wealth” by fostering a strong life sciences sector is failing, as the very companies central to that plan are now looking elsewhere for growth. The recent pull-back by pharmaceutical giants like MSD and Sanofi shows a fundamental breakdown in this strategic vision.
The “health and wealth” concept relies on a symbiotic relationship: the NHS gets access to innovative medicines, and in return, the UK economy benefits from pharmaceutical investment, R&D, and high-skilled jobs. However, the industry is now arguing that the UK is not holding up its end of the bargain.
Companies complain that the commercial terms in the UK—low spending, poor prices, high clawbacks—are so unfavorable that the “wealth” part of the equation no longer works. As a result, they are reducing their investment, which in turn threatens the “health” part by limiting the UK’s access to new research and medicines.
To salvage its core strategy, the government must restore this symbiotic balance. It needs to develop a new deal with the industry that recognizes that sustainable investment is contingent on a fair and competitive market. Without it, both the health and the wealth of the nation are at risk.